Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cevimeline hydrochloride
Drug ID BADD_D00425
Description Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Indications and Usage For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Marketing Status approved
ATC Code N07AX03
DrugBank ID DB00185
KEGG ID D00661
MeSH ID C059240
PubChem ID 123603
TTD Drug ID D0Q4CS
NDC Product Code 59651-422; 66406-0269; 0054-0334; 0713-0883; 40032-999; 46014-1002; 58159-087; 63395-201; 72888-118; 0713-0937; 42973-228; 72166-012; 43386-999; 16571-657
UNII P81Q6V85NP
Synonyms cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride
Chemical Information
Molecular Formula C10H18ClNOS
CAS Registry Number 107220-28-0
SMILES CC1OC2(CN3CCC2CC3)CS1.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Food poisoning12.03.01.024; 11.07.02.001; 07.11.01.007--Not Available
Fungal infection11.03.05.001--Not Available
Furuncle11.02.05.008; 23.11.02.009--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gamma-glutamyltransferase increased13.03.04.024--
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Gingival hypertrophy07.09.13.008--Not Available
Gingivitis11.01.04.013; 07.09.10.002--
Glaucoma06.03.01.002--
Glossitis07.14.01.001--Not Available
Glucocorticoids increased13.10.09.003--Not Available
Glycosuria20.02.01.005--
Goitre14.11.01.008; 05.02.01.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Granulocytopenia01.02.03.003--Not Available
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobinaemia01.06.04.001--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
Hallucination19.10.04.003--
Headache17.14.01.001--
Heat stroke24.06.02.009; 12.05.01.001--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis viral11.05.04.011; 09.01.09.007--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages